StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note released on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Price Performance
Shares of PULM stock opened at $2.23 on Tuesday. The company has a market cap of $8.14 million, a price-to-earnings ratio of -0.93 and a beta of 0.99. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $2.73. The firm has a fifty day moving average price of $2.03 and a 200-day moving average price of $1.92.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings results on Friday, May 10th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter. The business had revenue of $5.89 million during the quarter. Pulmatrix had a negative return on equity of 44.05% and a negative net margin of 75.73%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- What is Short Interest? How to Use It
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Pulmatrix Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pulmatrix and related companies with MarketBeat.com’s FREE daily email newsletter.
